Global Finance News
11 Aug 2026, 05:24
Alcon Stock Rises 3.5% After Hours as Q2 Sales Grow and 2026 Profit Outlook Improves
Alcon (NYSE: ALC) shares rose about 3.5% in after-hours trading after the eye-care company reported solid second-quarter 2026 growth and raised its full-year profitability and earnings outlook.
Second-quarter sales reached $2.78 billion, up 8% year-over-year on a reported basis and 7% in constant currency. Core diluted EPS increased 11% to $0.84 from $0.76 a year earlier.
New Products Drive Growth
Alcon attributed the quarter's momentum partly to newer products including UNITY, PanOptix Pro and TRYPTYR.
The Surgical segment generated approximately $1.57 billion in sales, up 8%, while Vision Care sales increased 8% to about $1.21 billion. Equipment and other surgical sales were particularly strong, jumping 26%, driven by recent launches including the UNITY platform. Ocular health sales increased 13%, supported by dry-eye products including TRYPTYR and Systane.
Underlying profitability also strengthened. Core operating income rose 17% to $574 million, while core operating margin expanded to 20.6% from 19.1% a year earlier.
Reported results were considerably weaker because Alcon recorded a $402 million pre-tax non-cash charge related to discontinuing the PowerVision IOL programs. That charge pushed reported diluted EPS to $0.00, compared with $0.35 last year, but does not affect the company's cash position or long-range financial objectives.
Alcon Raises 2026 Earnings Outlook
The guidance update appears to be an important factor behind the positive after-hours reaction.
Alcon maintained its constant-currency sales growth forecast at 5%-7%, but raised expected core operating-margin expansion to 90-190 basis points from 70-170 basis points. The company also increased its 2026 core diluted EPS growth forecast to 12%-15%, compared with its previous 10%-13% range.
Alcon also returned $469 million to shareholders during Q2 through dividends and share repurchases, bringing year-to-date capital returns to $538 million.
The roughly 3.5% after-hours gain suggests investors are focusing on the combination of healthy organic growth, improving core margins, successful new-product launches and a stronger earnings outlook, while largely looking through the sizable but non-cash PowerVision charge.
Alcon (NYSE: ALC) shares rose about 3.5% in after-hours trading after the eye-care company reported solid second-quarter 2026 growth and raised its full-year profitability and earnings outlook.
Second-quarter sales reached $2.78 billion, up 8% year-over-year on a reported basis and 7% in constant currency. Core diluted EPS increased 11% to $0.84 from $0.76 a year earlier.
New Products Drive Growth
Alcon attributed the quarter's momentum partly to newer products including UNITY, PanOptix Pro and TRYPTYR.
The Surgical segment generated approximately $1.57 billion in sales, up 8%, while Vision Care sales increased 8% to about $1.21 billion. Equipment and other surgical sales were particularly strong, jumping 26%, driven by recent launches including the UNITY platform. Ocular health sales increased 13%, supported by dry-eye products including TRYPTYR and Systane.
Underlying profitability also strengthened. Core operating income rose 17% to $574 million, while core operating margin expanded to 20.6% from 19.1% a year earlier.
Reported results were considerably weaker because Alcon recorded a $402 million pre-tax non-cash charge related to discontinuing the PowerVision IOL programs. That charge pushed reported diluted EPS to $0.00, compared with $0.35 last year, but does not affect the company's cash position or long-range financial objectives.
Alcon Raises 2026 Earnings Outlook
The guidance update appears to be an important factor behind the positive after-hours reaction.
Alcon maintained its constant-currency sales growth forecast at 5%-7%, but raised expected core operating-margin expansion to 90-190 basis points from 70-170 basis points. The company also increased its 2026 core diluted EPS growth forecast to 12%-15%, compared with its previous 10%-13% range.
Alcon also returned $469 million to shareholders during Q2 through dividends and share repurchases, bringing year-to-date capital returns to $538 million.
The roughly 3.5% after-hours gain suggests investors are focusing on the combination of healthy organic growth, improving core margins, successful new-product launches and a stronger earnings outlook, while largely looking through the sizable but non-cash PowerVision charge.
